zhengguangmycin and Mouth-Neoplasms

To compare the clinical efficacy and toxicity of teniposide (VM26) of higher dose with those of lower dose, both combined with cisplatin (CDDP) and pingyangmycin (PYM), in the treatment of patients with squamous cell carcinoma of oral and maxillofacial region (SCCOMR).. Sixty-five patients with SCCOMR entered into this study prospectively. Thirty-three patients were treated with higher dose of VM26 (total dose was 320 mg) combined with CDDP and PYM (PTP1), the other thirty-two patients were treated with lower dose (total dose was 158 mg) of VM26 combined with CDDP and PYM (PTP2).. Thirty-three patients received a total of 38 cycles of PTP1. The overall response rate was 81.82% (27/33). Thirty-two patients received a total of 36 cycles of PTP2 and showed overall response rate by 81.25% (26/32). There was no significant difference between PTP1 and PTP2 groups in response rate (P > 0.05). But the blood toxicity was more severe in PTP1 group than in PTP2 group (P < 0.01). Bone marrow depression rate (1-4 stage) was 48.48% in PTP1 group versus 25.00% in the other group.. A high response rate of 81.25% and relatively slighter adverse events could be obtained for lower dose of VM26 combined with CDDP and PYM (PTP2). So, the chemotherapy schedule, PTP2, a novel teniposide based regimen in SCCOMR could be employed and spread in clinical practice.

Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Humans; Male; Mouth Neoplasms; Prospective Studies; Teniposide

To evaluate the effect of locoregional immunotherapy of interleukin 2 (IL-2) in combination with chemotherapy upon intratumoral lymphocytes in oral squamous cell carcinomas.. Thirty-four patients with stage T3 or T4 oral squamous cell carcinoma were randomly divided into two groups, and treated with two therapies. 23 cases of them received immunochemotherapy and 11 cases received PVP chemotherapy. Changes of T lymphocyte subsets and B cells at tumor site in the two groups were compared before and after therapy.. The relative numbers of CD4+, CD8+, CD20+ before and after treatment in immunochemotherapy were respectively 36.96, 35.65, 28.65 and 56.61, 38.52, 38.70. The numbers of CD4+, CD20+ increased significantly after immunochemotherapy. However, in chemotherapy group, there was no significant difference in numbers of CD4+, CD8+ and CD20+ cells between pre and post treatment.. Immunochemotherapy for oral squamous cell carcinomas may play an important role in increasing local immunity.

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Humans; Injections, Intralesional; Interleukin-2; Male; Middle Aged; Mouth Neoplasms; T-Lymphocyte Subsets; Vincristine

Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Bleomycin; Child; Female; Hemangioma, Cavernous; Humans; Injections, Intralesional; Lip Neoplasms; Male; Middle Aged; Mouth Neoplasms

To study the differential expression of transforming growth factor beta 1 (TGF beta 1) in oral carcinoma and stroma lymphocytes by induction chemotherapy and inquire into the mechanism of TGF beta 1 information transmission.. Forty cases of oral tumor were treated with MTX, CDDP and PYM via subcutaneous implantable drug pump, in situ hybridization method was adopted to detect the expression of TGF beta 1 mRNA.. The positive expression of TGF beta 1 mRNA was enhanced in oral carcinoma (P < 0.05). After the induction chemotherapy via subcutaneous implantable drug pump, not only the expression level of TGF beta 1 in malignant cells of invading front zone was up-regulated (P < 0.05), but the expression level of stroma lymphocytes was higher than before.. These data demonstrated that TGF beta 1 not only has transforming potential, but also enhances the malignant progression of oral carcinoma. It was clear that TGF beta 1 can act as a tumor suppressor and a significant stimulator of T-cell-mediated tumor cytotoxity as well.

Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carcinoma, Squamous Cell; Female; Humans; Infusion Pumps, Implantable; Male; Methotrexate; Middle Aged; Mouth Neoplasms; RNA, Messenger; Transforming Growth Factor beta; Transforming Growth Factor beta1

The effects of intracellular glutathione (GSH) concentration on the toxicity of pingyangmycin in human squamous cell carcinoma cell line were evaluated. By using the GSH synthesis inhibitor D,L-buthionine-S,R-sulfoximine and the precursor of cysteine 2-oxothiazolidine-4-carboxylate (OTZ), intracellular glutathione levels were artificially changed. After exposed to different GSH concentrations cultured tumor cells were treated with pingyangmycin and the resultant mode of cell death was analyzed using morphological and biochemical criteria. It was found that the toxicity of pingyangmycin was obviously increased to cultured tumor cells on lowering GSH levels, with the mode of cell death switching from necrosis to apoptosis. In contract, treatment with OTZ increased GSH level compared with that of control cells, inhibited cell death induced by pingyangmycin via a necrotic rather than apoptotic process. These observations suggest that modulation of GSH levels effects the toxicity of pingyangmycin and that GSH influences the mode of cell death induced by pingyangmycin.

Topics: Antibiotics, Antineoplastic; Apoptosis; Bleomycin; Carcinoma, Squamous Cell; DNA Fragmentation; Enzyme-Linked Immunosorbent Assay; Glutathione; Humans; Intracellular Fluid; Mouth Neoplasms; Tumor Cells, Cultured

To study and evaluate the clinical effects of combined preoperative chemotherapy and their relations with multi drug resistance (MDR).. 102 cases with oral squamous cell carcinoma(OSCC) were included in the study (63 males and 39 females, aged 22 to 67 years). Among the subjects there were 57 cases with cancer of tongue and 45 cases with cancer of buccal mucosa. 27 cases in the group were classified as stage II, 55 as stage III and 20 cases as stage IV according to TNM standard. All cases accepted PYM + 5-Fu + DDP combined chemotherapy pre-operatively. The total given dose was PYM 48 mg, 5-Fu 7.5 g and DDP 300 mg. After the chemotherapy, radical surgery were performed within 2 weeks. The diagnosis of all cases were proved as OSCC by biopsy.. Total effective rate of the combined chemotherapy was 82.4%. All of the cases were followed up and their 3 years' survival rate was 67.6%.. The combined chemotherapy of PYM + 5-Fu + DDP is effective in using as one of comprehensive treatment for OSCC.

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Middle Aged; Mouth Neoplasms; Tongue Neoplasms; Treatment Outcome

To prepare the magnetic pingyangmycine-bearing microspheres (MPMs), test its characteristics, and evaluate the target ability of MPMs.. MPMs were prepared by a cold-condensation method at first. Then the scan electron microscope, high performance liquid chromatography (HPLC) and atomic absorption spectrometry were used to measure the diameter of MPMs and the contents of PYM and Fe3O4 in MPMs. Drug-releasing instrument was used to test the quantity of PYM released from MPMs. The distribution of intravenously injected MPMs in SD rat liver was investigated under an externally magnetic field.. MPMs are spherical with the mean diameter of 32.23 microns. The content of pingyangmycine in MPMs was 3.8% and Fe3O4 was 11.7% (w/w). The quantity of PYM released from MPMs in 3 hours was 63.1%. The content of Fe3O4 in the targeting sites of rats was obviously higher than that in the non-targeting sites (P < 0.01).. MPMs have good properties of drug-targeting and drug sustain releasing. MPMs may be ideal for the use of the treatment of cavernous hemangioma.

Topics: Animals; Bleomycin; Chromatography, High Pressure Liquid; Delayed-Action Preparations; Drug Administration Routes; Drug Delivery Systems; Hemangioma, Cavernous; Humans; Microspheres; Mouth Neoplasms; Pharmaceutical Preparations; Rats; Rats, Sprague-Dawley

The effect of Pinyangmycin, Dexamethasonum and Sodium Morrhuate injected concomitantly to treat cavernous hemangioma in oral and maxillofacial regions was evaluated.. The medical records of 350 patients with cavernous hemangioma in oral and maxillofacial regions between January 1998 and January 2002 were reviewed. One hundred and sixty-five of the patients were men, and 185 were women, the sex ratio was 1:1.12. The patients' ages were between 4 months and 55 years. Two hundred and Twenty-six hemangiomas were located in the maxillofacial regions, and 124 located in the oral cavity. The size of the lesions varied from 1 cm x 1 cm to 6 cm x 9 cm. Pinyangmycin, Dexamethasonum and Sodium Morrhuate were injected simultaneously into the lesions or in the vicinity of the cavernous hemangiomas, and the injection might be repeated every 5 to 7 days when necessary, and this process could be repeated 3 to 5 times.. Three hundred and fifty patients were followed up for 6-48 months. The cure and essentially cured rates were 95.48%, the total efficiency rate was 100%.. This method was a safe, simple and effective therapy to manage cavernous hemangioma in the oral and maxillofacial regions.

Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Preschool; Dexamethasone; Facial Neoplasms; Female; Hemangioma, Cavernous; Humans; Infant; Injections; Male; Maxillary Neoplasms; Middle Aged; Mouth Neoplasms; Sodium Morrhuate

The purpose of this study was to investigate the indication and therapeutic effects of Pingyangmycin injection as a primary therapy of lymphangiomas in oral, maxillofacial and cervical region.. A total of 195 patients (106 males and 89 females) with lymphangiomas in oral and maxillofacial regions were treated in the affiliated dental hospital of Sichuan University from May 1990 to December 2000. The patients' ages ranged from 0.5 to 46 years. The tongue was the most commonly involved site, followed by the cheek and the neck. The 200 lymphangiomas (5 patients had 2 lymphangiomas in different sites) underwent the therapy of Pingyangmycin, which was injected as with 1 mg/ml in saline. The total dose of Pingyangmycin ranged from 5 mg to 70 mg and 5 to 58 times, 1 time per 2-4 weeks.. The curative rate of cystic-type lymphangiomas was the highest. Of the 51 cystic lymphangiomas, 110 capillary lymphangiomas, 18 cavernous lymphangiomas and 21 combinations of capillary and cavenous lymphangiomas, the curative rates were respectively 100% (51), 46.36% (51), 16.16% (3) and 19.05% (4), which showed a significant therapeutic effect, respectively. And 40(78.43%), 19(17.27%), 2(11.11%) and 0(0%) of them completely disappeared. There was no serious side effect with Pingyangmycin-injection treatment, such as pulmonary fibrosis.. The treatment of injection of Pingyangmycin is a selective primary method of lymphangiomas, which can reduce the size of lymphangiomas, and make them completely disappeared.

Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Bleomycin; Child; Child, Preschool; Dexamethasone; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Infant; Injections, Intralesional; Lymphangioma; Male; Mouth Neoplasms; Tongue Neoplasms

To investigate the indication and result in hemangioma in oral and maxillofacial region with Pingyangmycin injection.. 1282 patients (554 males and 728 females) with hemangioma in oral and maxillofacial region have been treated in our hospital during the 10-year period from May 1990 to March 1999. The patients range between 0.5-84 years old. Lip, cheek and tongue were usually involved. 1211 patients were treated with injection of Pingyangmycin(about 0.89 mg/ml) and dexamethasone (about 0.55 mg/ml), 1 time/1-2 weeks.. The curative rates of cavernous hemangioma and strawberry hemangioma were 93.87% and 84.90%, but that of plexiform hemangioma was 22.22% and those of portwine stain and central hemangioma of the jaws were 0%, respectively. Serious complications associated with Pingyangmycin injection, such as pulmonary fibrosis were not seen.. Injection of Pingyangmycin is selective primary method for cavernous and strawberry hemangioma treatment.

Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Bleomycin; Child; Child, Preschool; Facial Neoplasms; Female; Hemangioma, Cavernous; Humans; Infant; Infant, Newborn; Injections, Intralesional; Jaw Neoplasms; Male; Middle Aged; Mouth Neoplasms

The antitumour antibiotic pingyangmycin (PYM; bleomycin A5) was isolated from many components of bleomycin (BLM) produced by Streptomyces pingyangensisn. PYM has a similar chemical structure to that of BLM but the terminal amine moiety is different. Therefore, it would be of significance to demonstrate the antitumour effect and action mechanism of PYM on cultivated tumour cells. In this study, we used the cell growth curve, plating efficiency, and DNA synthesis inhibition assay to demonstrate the cytotoxicity of PYM on cultured KB cells. In the meantime, the morphological variations of drug-treated cells were also observed. In addition, we used the DNA precipitation assay, a simple and rapid assay, for detecting DNA damage caused by PYM on cultured KB cells for potential genotoxicity. Our results indicate that the effect of PYM significantly inhibits the cell growth, colonyforming ability, and DNA synthesis of KB cells in a dose-dependent manner. Furthermore, when treated with 5 micrograms/ml of PYM for 24 h on cultured KB cells, DNA strand breaks can be induced (P < 0.05). Therefore, it is considered that the action mechanism of PYM is due to its ability to inhibit the synthesis of DNA and split the DNA chains.

Topics: Antibiotics, Antineoplastic; Bleomycin; Carcinoma, Squamous Cell; Cell Division; Cell Survival; DNA Damage; DNA, Neoplasm; Dose-Response Relationship, Drug; Humans; Mouth Neoplasms; Tumor Cells, Cultured; Tumor Stem Cell Assay

During 1984-1986, fifty-one patients, including 42 squamous cell carcinomas, 8 carcinomas of salivary gland origin and 1 malignant histiocytoma, were treated in our hospital using the PVP (CDDP, VCR and PINGYANGMYCIN) regimen or single CDDP. The response rate was 71.4% (30/42) for squamous cell carcinoma (CR 4 cases, PR 26 cases, NR 12 cases) with PVP, and 3/8 (all PR cases) for carcinoma of salivary gland origin (all adenoid cystic carcinomas) with CDDP. The authors indicate that besides the MTX and PINGYANGMYCIN, CDDP is another effective and useful drug for squamous cell carcinoma. When single dose (80-120 mg) is given by infusion with fluid and diuretics, it is very safe and (no need) worry about impairment of kidney function.

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Adenoid Cystic; Carcinoma, Squamous Cell; Cisplatin; Facial Neoplasms; Female; Humans; Jaw Neoplasms; Male; Middle Aged; Mouth Neoplasms; Vincristine

Topics: Adult; Antibiotics, Antineoplastic; Bleomycin; Carcinoma, Squamous Cell; Combined Modality Therapy; Facial Neoplasms; Female; Humans; Male; Middle Aged; Mouth Neoplasms; Premedication

Topics: Adult; Antibiotics, Antineoplastic; Bacterial Vaccines; Bleomycin; Carcinoma, Squamous Cell; Combined Modality Therapy; Corynebacterium; Female; Humans; Jaw Neoplasms; Male; Middle Aged; Mouth Neoplasms

Topics: Antibiotics, Antineoplastic; Bleomycin; Carcinoma, Squamous Cell; Facial Neoplasms; Humans; Maxillary Neoplasms; Mouth Neoplasms